CVS Health to Split Into Two Independent Public Companies

By EC Assets · Published 4 November 2026

CVS Health Corporation has announced its intent to separate into two independent, publicly traded companies. The strategic move will divide the company's retail pharmacies from its insurance and pharmacy-benefit operations. Shares fell up to 10 percent following the announcement, despite the company posting third-quarter financial results that exceeded market expectations. The transaction marks the breakup of a $117 billion healthcare empire. Under the restructuring, CVS will separate its network of retail drugstores from the Aetna insurance business and its pharmacy services division. The decision reverses the company's 2018 acquisition of Aetna, which was valued at $78 billion and originally established the vertically integrated healthcare conglomerate. At the time of that combination, the retail footprint encompassed 9,000 stores. Alongside the corporate separation, CVS reported its third-quarter 2026 financial results. The company beat consensus expectations for both revenue and earnings per share. CVS also raised its full-year 2026 guidance. However, the corporate separation surprised market analysts, leading the stock to decline in premarket trading and drop as much as 10 percent as investors weighed the breakup plan against the earnings performance. The breakup represents a major shift away from the large-scale integration of retail pharmacies, benefits management, and health insurance. By dismantling the corporate structure established through the 2018 Aetna transaction, CVS is reversing one of the largest corporate consolidations in the United States healthcare sector. The announcement was officially distributed via PR Newswire following the US midterm elections, after initially leaking to media on Election Day. Markets will track the execution timeline for creating the two independent, publicly traded entities, as well as the operational performance of the separate businesses under the raised full-year 2026 guidance. This article is intended for informational purposes only. It does not constitute investment advice.